IRB #

STUDY00015989

Title

A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED
UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to study the effects, good and bad, of the study drug KPT-330 versus placebo on participants and their advanced unresectable dedifferentiated liposarcoma.

Medical Condition(s)

advanced unresectable dedifferentiated liposarcoma

Eligibility Criteria

≥12 years old who have failed at least one prior treatment for their cancer. Further labs, scans, and review of medical history will be done to confirm eligibility.

Age Range

12 - 120

Healthy Volunteers Needed

No

Duration of Participation

For as long as the participant is seeing benefit from the study drug

Minors Included

Yes

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

Karyopharm Therapeutics Inc

Recruitment End

05/16/2018

Compensation Provided

No


Go Back